Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors
The agents currently approved for use in metastatic renal cell carcinoma (mRCC) can be divided broadly into two categories: (1) vascular endothelial growth factor receptor (VEGFR)-directed therapies or (2) inhibitors of the mammalian target of rapamycin (mTOR). The latter category includes everolimu...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2010-01-01
|
| Series: | Clinical Medicine Insights: Oncology |
| Online Access: | https://doi.org/10.4137/CMO.S1590 |
| _version_ | 1818242804856389632 |
|---|---|
| author | Sumanta Kumar Pal Robert A. Figlin |
| author_facet | Sumanta Kumar Pal Robert A. Figlin |
| author_sort | Sumanta Kumar Pal |
| collection | DOAJ |
| description | The agents currently approved for use in metastatic renal cell carcinoma (mRCC) can be divided broadly into two categories: (1) vascular endothelial growth factor receptor (VEGFR)-directed therapies or (2) inhibitors of the mammalian target of rapamycin (mTOR). The latter category includes everolimus and temsirolimus, both approved for distinct indications in mRCC. Everolimus gained its approval on the basis of phase III data showing a benefit in progression-free survival relative to placebo in patients previously treated with sunitinib and/or sorafenib. In contrast, temsirolimus was approved on the basis of a phase III trial in treatment-naïve patients with poor-risk mRCC, demonstrating an improvement in overall survival relative to interferon-alfa. While these pivotal trials have created unique positions for everolimus and temsirolimus in current clinical algorithms, the role of mTOR inhibitors in mRCC is being steadily revised and expanded through ongoing trials testing novel sequences and combinations. The clinical development of mTOR inhibitors is outlined herein. |
| first_indexed | 2024-12-12T13:51:03Z |
| format | Article |
| id | doaj.art-5a150fbb682244ae99d649a231e4d57c |
| institution | Directory Open Access Journal |
| issn | 1179-5549 |
| language | English |
| last_indexed | 2024-12-12T13:51:03Z |
| publishDate | 2010-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Oncology |
| spelling | doaj.art-5a150fbb682244ae99d649a231e4d57c2022-12-22T00:22:34ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492010-01-01410.4137/CMO.S1590Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR InhibitorsSumanta Kumar Pal0Robert A. Figlin1Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.The agents currently approved for use in metastatic renal cell carcinoma (mRCC) can be divided broadly into two categories: (1) vascular endothelial growth factor receptor (VEGFR)-directed therapies or (2) inhibitors of the mammalian target of rapamycin (mTOR). The latter category includes everolimus and temsirolimus, both approved for distinct indications in mRCC. Everolimus gained its approval on the basis of phase III data showing a benefit in progression-free survival relative to placebo in patients previously treated with sunitinib and/or sorafenib. In contrast, temsirolimus was approved on the basis of a phase III trial in treatment-naïve patients with poor-risk mRCC, demonstrating an improvement in overall survival relative to interferon-alfa. While these pivotal trials have created unique positions for everolimus and temsirolimus in current clinical algorithms, the role of mTOR inhibitors in mRCC is being steadily revised and expanded through ongoing trials testing novel sequences and combinations. The clinical development of mTOR inhibitors is outlined herein.https://doi.org/10.4137/CMO.S1590 |
| spellingShingle | Sumanta Kumar Pal Robert A. Figlin Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors Clinical Medicine Insights: Oncology |
| title | Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors |
| title_full | Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors |
| title_fullStr | Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors |
| title_full_unstemmed | Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors |
| title_short | Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors |
| title_sort | treatment options in metastatic renal cell carcinoma focus on mtor inhibitors |
| url | https://doi.org/10.4137/CMO.S1590 |
| work_keys_str_mv | AT sumantakumarpal treatmentoptionsinmetastaticrenalcellcarcinomafocusonmtorinhibitors AT robertafiglin treatmentoptionsinmetastaticrenalcellcarcinomafocusonmtorinhibitors |